新诊断乳腺癌:对比增强能谱乳腺X线与乳腺磁共振成像在病变范围评估中的比较
该回顾性研究纳入52例新诊断单侧乳腺癌女性,比较对比增强能谱乳腺X线与乳腺MR成像在检出原发癌和继发癌中的诊断性能,以组织学或影像随访为标准。对比增强能谱乳腺X线敏感度与MR相近(94% vs 99%),阳性预测值显著更高(93% vs 60%),假阳性更少(5 vs 45),并检出全部11个继发癌(MR检出10个)。
要点
- 对比增强能谱乳腺X线敏感度94%(66/70),MR为99%(69/70),两者相近。
- 对比增强能谱乳腺X线阳性预测值93%(66/71),MR为60%(69/115),前者显著更高。
- 对比增强能谱乳腺X线检出11/11继发癌(100%),MR检出10/11(91%)。
核心结论
- 对比增强能谱乳腺X线在评估新诊断乳腺癌病变范围方面敏感度可能与MR成像相当,且阳性预测值更高。
研究设计与样本
- 经机构审查委员会批准、符合HIPAA的回顾性研究,纳入2014年3月至2015年10月间52例新诊断单侧乳腺癌女性,均行乳腺MR成像和对比增强能谱乳腺X线,以组织学或影像随访为标准参考;其中46例因MR发现额外可疑病灶转诊行对比增强能谱乳腺X线和靶向超声,6例在外院确诊后转诊行对比增强能谱乳腺X线和靶向超声作为诊断成像的一部分;图像由两名接受专科培训、具有2.5年对比增强能谱乳腺X线经验的乳腺影像医师分析。
诊断标准与关键数值
- 对比增强能谱乳腺X线敏感度94%(66/70病灶),MR成像敏感度99%(69/70病灶)。
- 对比增强能谱乳腺X线阳性预测值93%(66/71病灶),MR成像阳性预测值60%(69/115病灶)。
- 对比增强能谱乳腺X线假阳性5个,MR成像假阳性45个(P < .001)。
- 对比增强能谱乳腺X线检出继发癌11/11(100%),MR成像检出10/11(91%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To compare the diagnostic performances of contrast material-enhanced spectral mammography and breast magnetic resonance (MR) imaging in the detection of index and secondary cancers in women with newly diagnosed breast cancer by using histologic or imaging follow-up as the standard of reference. Materials and Methods This institutional review board-approved, HIPAA-compliant, retrospective study included 52 women who underwent breast MR imaging and contrast-enhanced spectral mammography for newly diagnosed unilateral breast cancer between March 2014 and October 2015. Of those 52 patients, 46 were referred for contrast-enhanced spectral mammography and targeted ultrasonography because they had additional suspicious lesions at MR imaging. In six of the 52 patients, breast cancer had been diagnosed at an outside institution. These patients were referred for contrast-enhanced spectral mammography and targeted US as part of diagnostic imaging. Images from contrast-enhanced spectral mammography were analyzed by two fellowship-trained breast imagers with 2.5 years of experience with contrast-enhanced spectral mammography. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated for both imaging modalities and compared by using the Bennett statistic. Results Fifty-two women with 120 breast lesions were included for analysis (mean age, 50 years; range, 29-73 years). Contrast-enhanced spectral mammography had similar sensitivity to MR imaging (94% [66 of 70 lesions] vs 99% [69 of 70 lesions]), a significantly higher PPV than MR imaging (93% [66 of 71 lesions] vs 60% [69 of 115 lesions]), and fewer false-positive findings than MR imaging (five vs 45) (P < .001 for all results). In addition, contrast-enhanced spectral mammography depicted 11 of the 11 secondary cancers (100%) and MR imaging depicted 10 (91%). Conclusion Contrast-enhanced spectral mammography is potentially as sensitive as MR imaging in the evaluation of extent of disease in newly diagnosed breast cancer, with a higher PPV. © RSNA, 2017.
引用
- Lee-Felker SA, Tekchandani L, Thomas M, et al. Newly Diagnosed Breast Cancer: Comparison of Contrast-enhanced Spectral Mammography and Breast MR Imaging in the Evaluation of Extent of Disease. Radiology. 2017. PMID: 28654337. doi:10.1148/radiol.2017161592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。